Video
Dr. Petrylak on important updates in bladder cancer from NY GU 2022
Author(s):
“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.
Video Player is loading.
In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.
Related Videos
Case 1: A 79-Year-Old Man With Non–Muscle-Invasive Bladder Cancer
Non–Muscle Invasive-Bladder Cancer Overview
Laura Davis, MD, on link between microplastics and bladder cancer
Rebecca A. Campbell, MD, discusses citation rates for men and women in the oncology literature
Preston Sprenkle, MD, highlights trial of TULSA vs radical prostatectomy
Sam Chang, MD, shares updated data on nogapendekin alfa inbakicept in NMIBC
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
Related Content
